Ftse Mib
32.665,21
-2,81%
DAX
18.002,02
-1,43%
S&P 500
5.431,60
-0,04%
NASDAQ
17.688,88
0,12%
Bitcoin
66.344,49
-0,44%
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Fortress Biotech Inc (FBIO) Fortress Biotech Inc (FBIO) Notizie

FBIO

Fortress Biotech (FBIO)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:FBIO
DataOraFonteTitoloSimboloCompagnia
16/05/202414:30GlobeNewswire Inc.Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)NASDAQ:FBIOFortress Biotech Inc
16/05/202414:00GlobeNewswire Inc.Fortress Biotech to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company ShowcaseNASDAQ:FBIOFortress Biotech Inc
15/05/202422:15GlobeNewswire Inc.Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:FBIOFortress Biotech Inc
15/05/202422:01GlobeNewswire Inc.Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company ShowcaseNASDAQ:FBIOFortress Biotech Inc
15/05/202414:30GlobeNewswire Inc.Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:FBIOFortress Biotech Inc
14/05/202414:30GlobeNewswire Inc.Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver TransplantationNASDAQ:FBIOFortress Biotech Inc
13/05/202422:01GlobeNewswire Inc.Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:FBIOFortress Biotech Inc
07/05/202414:30GlobeNewswire Inc.Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024NASDAQ:FBIOFortress Biotech Inc
02/05/202422:01GlobeNewswire Inc.Mustang Bio Announces Closing of $4 Million Public OfferingNASDAQ:FBIOFortress Biotech Inc
01/05/202422:01GlobeNewswire Inc.Journey Medical Corporation Appoints Joseph Benesch as Chief Financial OfficerNASDAQ:FBIOFortress Biotech Inc
30/04/202402:00GlobeNewswire Inc.Mustang Bio Announces Pricing of $4 Million Public OfferingNASDAQ:FBIOFortress Biotech Inc
29/04/202414:00GlobeNewswire Inc.Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross ProceedsNASDAQ:FBIOFortress Biotech Inc
25/04/202414:30GlobeNewswire Inc.Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024NASDAQ:FBIOFortress Biotech Inc
24/04/202413:30GlobeNewswire Inc.Avenue Therapeutics Announces Reverse Stock SplitNASDAQ:FBIOFortress Biotech Inc
28/03/202421:05GlobeNewswire Inc.Fortress Biotech Reports 2023 Financial Results and Recent Corporate HighlightsNASDAQ:FBIOFortress Biotech Inc
28/03/202414:00GlobeNewswire Inc.Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune DiseasesNASDAQ:FBIOFortress Biotech Inc
25/03/202413:30GlobeNewswire Inc.Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024NASDAQ:FBIOFortress Biotech Inc
21/03/202421:01GlobeNewswire Inc.Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate HighlightsNASDAQ:FBIOFortress Biotech Inc
18/03/202421:05GlobeNewswire Inc.Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate HighlightsNASDAQ:FBIOFortress Biotech Inc
18/03/202413:30GlobeNewswire Inc.Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of RosaceaNASDAQ:FBIOFortress Biotech Inc
15/03/202413:30GlobeNewswire Inc.Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024NASDAQ:FBIOFortress Biotech Inc
15/03/202413:15GlobeNewswire Inc.Avenue Therapeutics Receives Positive Listing Determination from NasdaqNASDAQ:FBIOFortress Biotech Inc
13/03/202413:30GlobeNewswire Inc.Journey Medical Corporation to Participate in the 36th Annual ROTH ConferenceNASDAQ:FBIOFortress Biotech Inc
12/03/202413:30GlobeNewswire Inc.Fortress Biotech to Participate in 36th Annual ROTH ConferenceNASDAQ:FBIOFortress Biotech Inc
11/03/202413:30GlobeNewswire Inc.Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual MeetingNASDAQ:FBIOFortress Biotech Inc
11/03/202413:00GlobeNewswire Inc.Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual MeetingNASDAQ:FBIOFortress Biotech Inc
07/03/202413:30GlobeNewswire Inc.Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade GliomaNASDAQ:FBIOFortress Biotech Inc
04/03/202414:30GlobeNewswire Inc.Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes DiseaseNASDAQ:FBIOFortress Biotech Inc
22/02/202414:30GlobeNewswire Inc.Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence EpilepsyNASDAQ:FBIOFortress Biotech Inc
11/01/202414:30GlobeNewswire Inc.Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology ConferenceNASDAQ:FBIOFortress Biotech Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:FBIO

La tua Cronologia

BIT
F17266
Vontobel Financial Produ...
BIT
P1EM69
BNP Paribas Issuance
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network